FDA approves lemborexant for treatment of insomnia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that the U.S. Food and Drug Administration has approved Dayvigo (lemborexant) 5 mg and 10 mg for the treatment of adult patients with sleep-onset insomnia and sleep maintenance insomnia. According to Eisai, the [...]